Abstract
Objective To study the effect of moxifloxacin in the treatment of patients with multidrug-resistant tuberculosis .Methods 96 patients with multidrug-resistant tuberculosis were randomly divided into the two groups . The observation group（n=48 cases） was treated by moxifloxacin,and the control group（n=48 cases） was treated by levofloxacin.They were treated for 12 months.3,6,12 months after treatment,sputum smears were taken,and the adverse reactions were observed .Serum vasoactive intestinal peptide （ VIP） level was measured before and after treat-ment.Results 3,6,12 months after treatment,the sputum negative rates in the observation group were 36.0%, 87.5%,95.8%,which were significantly higher than 62.5%,77.1%,83.3% in the control group （χ2 =5.12, 5.96,7.28,all P〈0.05）.The total effective rate of the control group was 83.3%,which was significantly lower than 95.8%of the observation group （χ2 =5.28,P〈0.05）.Serum VIP levels in the control group and observation group were （29.3 ±6.7）ng/L,（20.7 ±5.4）ng/L.After treatment,the serum VIP levels in the two groups were significant-ly decreased,and the serum VIP level of the observation group was lower compared with the control group （t=3.01, P〈0.05）.During treatment,neutropenia,the incidence rates of gastrointestinal side effects ,liver damage and neuro-logical symptoms and other adverse reactions had no significant differences between the two groups （χ2 =1.56,1.74, 2.02,0.00,all P〉0.05）.Conclusion Moxifloxacin is better than levofloxacin in the treatment of patients with multidrug-resistant tuberculosis. Key words: Extensively drug-resistant tuberculosis; Tuberculosis,pulmonary; Moxifloxacin
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
